Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06658730 · ClinicalTrials.gov registry record
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
A clinical trial of Vascular Disease and Intramural Hematoma, sponsored by W.L.Gore & Associates.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 10
- Study locations
NCT06658730 is a study of Vascular Disease and Intramural Hematoma that is actively recruiting participants, run by W.L.Gore & Associates. The registered enrollment target is 1,500 participants, above the 638-participant average among 9 other Vascular Disease trials with a reported enrollment target (135% higher). The trial reports 10 study locations across 4 states.
The verdict
NCT06658730, a study of Vascular Disease and Intramural Hematoma, is actively recruiting participants, sponsored by W.L.Gore & Associates.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 10
- Study locations
Study Summary
An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-market registry for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System (CTAG w/AC) is intended to demonstrate that thoracic endovascular aortic repair (TEVAR) for lesions of the descending thoracic aorta continues to be a suitable treatment option for appropriately selected patients.
Conditions Studied
Interventions
- DEVICE Endovascular
Study Locations (10)
Other
- Rigshospitalet - Copenhagen
- Centre Hospitalier Universitaire Strasbourg - Strasbourg
- Universitatsmedizin Frankfurt - Frankfurt
- Regensburg University Hospital - Regensburg
- Laiko General Hospital of Athens - Athens
- Hospital Universitari de Bellvitge - Barcelona
- Uppsala University - Uppsala
California
- Cedars-Sinai Medical Center - Los Angeles
Indiana
- Indiana University School of Medicine - Indianapolis
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2025-06-19 |
| Est. Completion | 2038-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06658730
The ClinicalTrials.gov registry entry for NCT06658730 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 638-participant average among 9 other Vascular Disease trials with a reported enrollment target (135% higher). The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Vascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Endovascular is the first listed.
NCT06658730 reports 10 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT06658730 about?
NCT06658730 is a clinical study titled "Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance". An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-ma...
What is the current status of trial NCT06658730?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2025-06-19. Estimated completion is 2038-08.
What conditions does trial NCT06658730 study?
This clinical trial studies the following conditions: Vascular Disease, Intramural Hematoma, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta.
What interventions are being tested in trial NCT06658730?
The interventions under investigation include: Endovascular (DEVICE).
Who is sponsoring clinical trial NCT06658730?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06658730 being conducted?
This trial has 10 study locations across California, Indiana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Studies of Neuregulin/ERBB Signaling in Human Heart
RECRUITING
-
Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA)
COMPLETED · Phase 1
-
Study of Abnormal Blood Clotting in Children With Stroke
COMPLETED
-
Healthy Heart Amputation Rehabilitation Treatment (H.A.R.T)
COMPLETED · Phase 2
-
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
COMPLETED · Phase 1
-
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.